These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

831 related articles for article (PubMed ID: 30039219)

  • 21. Improving MGMT methylation status prediction of glioblastoma through optimizing radiomics features using genetic algorithm-based machine learning approach.
    Do DT; Yang MR; Lam LHT; Le NQK; Wu YW
    Sci Rep; 2022 Aug; 12(1):13412. PubMed ID: 35927323
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Arterial spin labeling perfusion-weighted imaging aids in prediction of molecular biomarkers and survival in glioblastomas.
    Yoo RE; Yun TJ; Hwang I; Hong EK; Kang KM; Choi SH; Park CK; Won JK; Kim JH; Sohn CH
    Eur Radiol; 2020 Feb; 30(2):1202-1211. PubMed ID: 31468161
    [TBL] [Abstract][Full Text] [Related]  

  • 23. MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma.
    Donson AM; Addo-Yobo SO; Handler MH; Gore L; Foreman NK
    Pediatr Blood Cancer; 2007 Apr; 48(4):403-7. PubMed ID: 16609952
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Incremental Prognostic Value of ADC Histogram Analysis over MGMT Promoter Methylation Status in Patients with Glioblastoma.
    Choi YS; Ahn SS; Kim DW; Chang JH; Kang SG; Kim EH; Kim SH; Rim TH; Lee SK
    Radiology; 2016 Oct; 281(1):175-84. PubMed ID: 27120357
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The tumoral A genotype of the MGMT rs34180180 single-nucleotide polymorphism in aggressive gliomas is associated with shorter patients' survival.
    Fogli A; Chautard E; Vaurs-Barrière C; Pereira B; Müller-Barthélémy M; Court F; Biau J; Pinto AA; Kémény JL; Khalil T; Karayan-Tapon L; Verrelle P; Costa BM; Arnaud P
    Carcinogenesis; 2016 Feb; 37(2):169-176. PubMed ID: 26717998
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Apparent diffusion coefficient obtained by magnetic resonance imaging as a prognostic marker in glioblastomas: correlation with MGMT promoter methylation status.
    Romano A; Calabria LF; Tavanti F; Minniti G; Rossi-Espagnet MC; Coppola V; Pugliese S; Guida D; Francione G; Colonnese C; Fantozzi LM; Bozzao A
    Eur Radiol; 2013 Feb; 23(2):513-20. PubMed ID: 22875158
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of temozolomide is correlated with 1p loss and methylation of the deoxyribonucleic acid repair gene MGMT in malignant gliomas.
    Ishii D; Natsume A; Wakabayashi T; Hatano H; Asano Y; Takeuchi H; Shimato S; Ito M; Fujii M; Yoshida J
    Neurol Med Chir (Tokyo); 2007 Aug; 47(8):341-9; discussion 350. PubMed ID: 17721049
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Noninvasive Assessment of O(6)-Methylguanine-DNA Methyltransferase Promoter Methylation Status in World Health Organization Grade II-IV Glioma Using Histogram Analysis of Inflow-Based Vascular-Space-Occupancy Combined with Structural Magnetic Resonance Imaging.
    He W; Li X; Hua J; Liao S; Guo L; Xiao X; Liu X; Zhou J; Wang W; Xu Y; Wu Y
    J Magn Reson Imaging; 2021 Jul; 54(1):227-236. PubMed ID: 33590929
    [TBL] [Abstract][Full Text] [Related]  

  • 29. MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial.
    Weller M; Tabatabai G; Kästner B; Felsberg J; Steinbach JP; Wick A; Schnell O; Hau P; Herrlinger U; Sabel MC; Wirsching HG; Ketter R; Bähr O; Platten M; Tonn JC; Schlegel U; Marosi C; Goldbrunner R; Stupp R; Homicsko K; Pichler J; Nikkhah G; Meixensberger J; Vajkoczy P; Kollias S; Hüsing J; Reifenberger G; Wick W;
    Clin Cancer Res; 2015 May; 21(9):2057-64. PubMed ID: 25655102
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association of MGMT Promoter Methylation Status With Survival Outcomes in Patients With High-Risk Glioma Treated With Radiotherapy and Temozolomide: An Analysis From the NRG Oncology/RTOG 0424 Trial.
    Bell EH; Zhang P; Fisher BJ; Macdonald DR; McElroy JP; Lesser GJ; Fleming J; Chakraborty AR; Liu Z; Becker AP; Fabian D; Aldape KD; Ashby LS; Werner-Wasik M; Walker EM; Bahary JP; Kwok Y; Yu HM; Laack NN; Schultz CJ; Gray HJ; Robins HI; Mehta MP; Chakravarti A
    JAMA Oncol; 2018 Oct; 4(10):1405-1409. PubMed ID: 29955793
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combinations of four or more CpGs methylation present equivalent predictive value for MGMT expression and temozolomide therapeutic prognosis in gliomas.
    Chai RC; Zhang KN; Liu YQ; Wu F; Zhao Z; Wang KY; Jiang T; Wang YZ
    CNS Neurosci Ther; 2019 Mar; 25(3):314-322. PubMed ID: 30117294
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Correlation of apparent diffusion coefficient values measured by diffusion MRI and MGMT promoter methylation semiquantitatively analyzed with MS-MLPA in patients with glioblastoma multiforme.
    Sunwoo L; Choi SH; Park CK; Kim JW; Yi KS; Lee WJ; Yoon TJ; Song SW; Kim JE; Kim JY; Kim TM; Lee SH; Kim JH; Sohn CH; Park SH; Kim IH; Chang KH
    J Magn Reson Imaging; 2013 Feb; 37(2):351-8. PubMed ID: 23023975
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Correlation of the quantitative level of MGMT promoter methylation and overall survival in primary diagnosed glioblastomas using the quantitative MethyQESD method.
    von Rosenstiel C; Wiestler B; Haller B; Schmidt-Graf F; Gempt J; Bettstetter M; Rihani L; Wu W; Meyer B; Schlegel J; Liesche-Starnecker F
    J Clin Pathol; 2020 Feb; 73(2):112-115. PubMed ID: 31422371
    [TBL] [Abstract][Full Text] [Related]  

  • 34. IDH1 mutation and MGMT methylation status predict survival in patients with anaplastic astrocytoma treated with temozolomide-based chemoradiotherapy.
    Minniti G; Scaringi C; Arcella A; Lanzetta G; Di Stefano D; Scarpino S; Bozzao A; Pace A; Villani V; Salvati M; Esposito V; Giangaspero F; Enrici RM
    J Neurooncol; 2014 Jun; 118(2):377-383. PubMed ID: 24748470
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Noninvasive O
    Hajianfar G; Shiri I; Maleki H; Oveisi N; Haghparast A; Abdollahi H; Oveisi M
    World Neurosurg; 2019 Dec; 132():e140-e161. PubMed ID: 31505292
    [TBL] [Abstract][Full Text] [Related]  

  • 36. O(6)-Methylguanine DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression is correlated with progression-free survival in patients with glioblastoma.
    Sonoda Y; Yokosawa M; Saito R; Kanamori M; Yamashita Y; Kumabe T; Watanabe M; Tominaga T
    Int J Clin Oncol; 2010 Aug; 15(4):352-8. PubMed ID: 20232102
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MGMT promoter methylation determined by the MGMT-STP27 algorithm is not predictive for outcome to temozolomide in IDH-mutant anaplastic astrocytomas.
    Tesileanu CMS; Gorlia T; Golfinopoulos V; French PJ; van den Bent MJ
    Neuro Oncol; 2022 Apr; 24(4):665-667. PubMed ID: 35099533
    [No Abstract]   [Full Text] [Related]  

  • 38. Predicting MGMT Promoter Methylation of Glioblastoma from Dynamic Susceptibility Contrast Perfusion: A Radiomic Approach.
    Crisi G; Filice S
    J Neuroimaging; 2020 Jul; 30(4):458-462. PubMed ID: 32374045
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic and predictive roles of MGMT protein expression and promoter methylation in sporadic pancreatic neuroendocrine neoplasms.
    Schmitt AM; Pavel M; Rudolph T; Dawson H; Blank A; Komminoth P; Vassella E; Perren A
    Neuroendocrinology; 2014; 100(1):35-44. PubMed ID: 25012122
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Radiomics and MGMT promoter methylation for prognostication of newly diagnosed glioblastoma.
    Sasaki T; Kinoshita M; Fujita K; Fukai J; Hayashi N; Uematsu Y; Okita Y; Nonaka M; Moriuchi S; Uda T; Tsuyuguchi N; Arita H; Mori K; Ishibashi K; Takano K; Nishida N; Shofuda T; Yoshioka E; Kanematsu D; Kodama Y; Mano M; Nakao N; Kanemura Y
    Sci Rep; 2019 Oct; 9(1):14435. PubMed ID: 31594994
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 42.